Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,213 JPY | -1.51% | +0.09% | +17.03% |
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company benefits from high valuations in earnings multiples.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+17.03% | 121M | - | - | |
+29.68% | 699B | C+ | ||
+25.07% | 571B | B | ||
-4.35% | 364B | C+ | ||
+17.65% | 326B | B- | ||
+3.77% | 286B | C+ | ||
+14.68% | 236B | B+ | ||
+4.71% | 198B | B- | ||
-12.43% | 194B | A+ | ||
-3.79% | 154B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4538 Stock
- Ratings Fuso Pharmaceutical Industries,Ltd.